1g IV q24h
0 - 29 eGFR30+ eGFR500mg IV q24h1g IV q24h
500mg IV daily, dose after dialysis on HD days
Targeted therapy of ESBL infections and other resistant gram negative infections.
Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.
Immediate and delayed-type allergy
Cytopenias, eosinophilia, positive Coombs
Liver enzyme abnormalities
Seizure risk lower than other carbapenems
Antimicrobial class: Carbapenem
Pregnancy category: B
Average serum half life: 4.0
Urine penetration: Therapeutic
Lung penetration: Therapeutic
Biliary penetration: Moderate